Myomo (MYO) insider sale leaves CMO holding 105,733 shares

Rhea-AI Filing Summary

MYOMO, INC. (MYO) reports an amended insider transaction for Chief Medical Officer Harry Kovelman. On August 20, 2026, he executed an open-market sale of 17,500 shares of common stock at a weighted average price of $1.7331 per share, with individual trade prices ranging from $1.72 to $1.75. Following this transaction, he beneficially owned 105,733 shares of MYO common stock. The amendment corrects the originally reported shares sold and resulting holdings; no other aspects of the prior filing were changed.

Insider Trade Summary

Net Seller: 17,500 shares

Net Sell 1 txn

Insider Kovelman Harry

Role Chief Medical Officer

Sold 17,500 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	17,500	$1.7331	$30K

Holdings After Transaction: Common Stock — 105,733 shares (Direct)

Footnotes (1)

1. F1. Represents weighted average sales price. Shares sold in open market transactions in multiple lots at prices ranging from $1.72 to $1.75 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

Key Figures

Shares sold: 17,500 shares Weighted average sale price: $1.7331 per share Sale price range: $1.72–$1.75 per share +1 more

4 metrics

Shares sold 17,500 shares Common stock sold by Chief Medical Officer on August 20, 2026

Weighted average sale price $1.7331 per share Weighted average price for the 17,500 shares sold

Sale price range $1.72–$1.75 per share Prices of multiple open-market lots included in the sale

Shares beneficially owned after transaction 105,733 shares Direct holdings of Harry Kovelman following the sale

Key Terms

beneficially owned, weighted average sales price, open market transactions

3 terms

beneficially owned financial

"correct the number of shares sold and the resultant amount of shares beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

weighted average sales price financial

"Represents weighted average sales price. Shares sold in open market"

open market transactions financial

"Shares sold in open market transactions in multiple lots at prices"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

FAQ

What insider transaction did MYO report in this amended Form 4/A?

The company reported that Chief Medical Officer Harry Kovelman sold 17,500 shares of MYOMO, INC. common stock on August 20, 2026 in an open-market transaction at a weighted average price of $1.7331 per share, with prices ranging from $1.72 to $1.75.

How many MYO shares does Harry Kovelman beneficially own after the sale?

After the reported sale, Chief Medical Officer Harry Kovelman beneficially owned 105,733 shares of MYOMO, INC. common stock. This figure reflects his direct holdings following the 17,500-share sale on August 20, 2026.

What price did the MYO shares sell for in the insider transaction?

The insider sale was executed at a weighted average price of $1.7331 per MYO share. According to the disclosure, the shares were sold in multiple open-market lots at prices ranging from $1.72 to $1.75 per share.

Why was this MYO Form 4/A filed as an amendment?

The Form 4/A was filed to correct the number of shares sold by Harry Kovelman and the resulting amount of shares beneficially owned after the transactions. The company states that no other amendments were made to the original Form 4 filed on August 21, 2026.

Was the MYO insider sale made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed for these transactions, and no footnote describes a trading plan. The sale is identified as an open market transaction with a weighted average price disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/24/2026 - 08:08 AM Accepted by SEC EDGAR 08/24/2026 - 08:08 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kovelman Harry

(Last) (First) (Middle)

C/O MYOMO, INC.

45 BLUE SKY DR., SUITE 101

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/21/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2026		S		17,500	D	$1.7331(1)	105,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents weighted average sales price. Shares sold in open market transactions in multiple lots at prices ranging from $1.72 to $1.75 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

Remarks:

This Form 4/A is being filed to correct the number of shares sold and the resultant amount of shares beneficially owned following the transactions. No other amendments to the original Form 4, which was filed on August 21, 2026.

	/s/ David A. Henry, Attorney-in-Fact	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)